Bionexus Gene Lab (BGLC) GlobeNewswire News Room·2024-09-12 17:23Core Viewpoint - BioNexus Gene Lab Corp. has signed a strategic partnership MOU with Shenzhen Rongguang Health Group to enhance cancer screening, precision medicine, and preventative healthcare through its subsidiary MRNA Scientific Sdn Bhd [1][2]. Group 1: Partnership Objectives - The partnership aims to leverage both companies' expertise to tackle critical healthcare challenges and improve patient outcomes [3]. - Key objectives include: - Expansion of Cancer Screening and Diagnostics: MRNA Scientific Sdn Bhd will enhance cancer screening capabilities in Southeast Asia and China through advanced genomic testing and molecular diagnostics [3]. - Research and Development in Regenerative Medicine: Collaboration will focus on advanced healthcare technologies, including non-cellular exosome therapy and regenerative medicine, for anti-aging therapies and chronic disease management [3]. - Preventative Healthcare and Chronic Disease Management: The partnership will improve preventative healthcare services and personalized healthcare plans based on advanced diagnostics [3]. - Synergy in Technological Innovation: Combining diagnostic capabilities with established healthcare platforms will create synergies for healthcare innovation, improving disease detection, prevention, and treatment [3]. Group 2: Company Statements - The CEO of BioNexus Gene Lab Corp. emphasized that this partnership is a pivotal moment for the company, advancing efforts in cancer screening and expanding into broader healthcare solutions [4].